ArticleJACC. Advances2026
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients do not reach recommended low-density lipoprotein cholesterol (LDL-C) levels on statins alone. Inclisiran is a small interfering RNA providing ∼50% further reduction in LDL-C.
objectivesThe authors estimated the number of U.S. adults eligible for inclisiran and the number of preventable atherosclerotic cardiovascular disease (ASCVD) events with inclisiran use.
methodsUsing a cross-sectional study of the National Health and Nutrition Examination Survey 2011 to 2020, the authors identified 3 cohorts: high-risk primary prevention (≥20% 10-year ASCVD risk or 7.5% to <20% with ≥2 risk-enhancing factors), diabetes, and secondary prevention. Included adults were ≥18 years with LDL-C ≥70 mg/dL (≥55 mg/dL if very high-risk for ASCVD events) despite statin therapy. The ASCVD Pooled Cohort Equation and SMART2 risk score were used to estimate ASCVD events in 10 years "without inclisiran." Preventable ASCVD events were calculated "with inclisiran" using inclisiran trial data to estimate LDL-C reduction and Cholesterol Treatment Trialists' data to estimate reductions in ASCVD events per mmol/L of LDL-C.
resultsAmong the high-risk primary prevention, diabetes, and secondary prevention cohorts, the authors estimated 5.4 million, 6.5 million, and 8.0 million U.S. adults, respectively, to be eligible for inclisiran. Based on 34.5%, 29.0%, and 29.0% respective risk reductions, the authors estimated ∼448,600, ∼459,800, and ∼711,000 ASCVD events could be prevented over 10 years with inclisiran. Most preventable ASCVD events occurred among males and White patients.
conclusionsApproximately 20 million U.S. adults with inadequately controlled LDL-C may be eligible for inclisiran, with the potential to prevent over 1.6 million ASCVD events over 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.